Amongst sufferers within the relapsed/refractory and treatment-naive settings with Bruton tyrosine kinase inhibitor–naive persistent lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), Jaypirca...
Jaypirca (pirtobrutinib) was discovered to have related efficacy as Imbruvica (ibrutinib) in enhancing medical efficacy in sufferers with persistent lymphocytic leukemia (CLL)...
